Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets, which are approved for renal cell carcinoma and previously treated hepatocellular carcinoma; COMETRIQ® (cabozantinib) capsules, which are approved for progressive, metastatic medullary thyroid cancer; COTELLIC® (cobimetinib), which is an inhibitor of MEK approved as part of a combination regimen to treat melanoma; and MINNEBRO® (esaxerenone), which is an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension. The EXEL stock yearly return is shown above.
The yearly return on the EXEL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the EXEL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|